en · de · es · pt
aod-9604-notes.peptides6608.com › Faq › Identity And Research Origin — Evidence Review

Identity And Research Origin — Evidence Review

By Editorial Desk · published 2025-07-03 · last reviewed 2025-08-17 · Faq

mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-08-17 and is reviewed periodically as new material appears.

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

Aod-9604 at a glance

PropertyValueNotes
Molecular classPeptide fragmentCorresponds to hGH residues 176-191
Common synonymsAOD9604, hGH 176-191Also written as AOD-9604
Typical formLyophilized powderOften supplied in sealed vials
SolubilityWater-solubleDissolves in aqueous buffers
Regulatory statusNot approved as drugBanned in sport; varies by country

Background And Research Context

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

Related pages on this site

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

Identity And Research Background

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

Further detail

Daisy was the most famous campaign commercial of the Cold War. Aired only once, on 7 September 1964, it was a factor in Lyndon B. Johnson's defeat of Barry Goldwater in the 1964 presidential election. The contents of the commercial were controversial, and their emotional impact was searing. The commercial opens with a very young girl standing in a meadow with chirping birds, slowly counting the petals of a daisy as she picks them one by one. Her sweet innocence, along with mistakes in her counting, endear her to the viewer. When she reaches "9", an ominous-sounding male voice is suddenly heard intoning the countdown of a rocket launch. As the girl's eyes turn toward something she sees in the sky, the camera zooms in until one of her pupils fills the screen, blacking it out. The countdown reaches zero, and the blackness is instantly replaced by a simultaneous bright flash and thunderous sound which is then followed by footage of a nuclear explosion, an explosion similar in appearance to the near surface burst Trinity test of 1945, followed by another cut to footage of a billowing mushroom cloud. As the fireball ascends, an edit cut is made, this time to a close-up section of incandescence in the mushroom cloud, over which a voiceover from Johnson is played, which states emphatically, "These are the stakes! To make a world in which all of God's children can live, or to go into the dark. We must either love each other, or we must die." Another voiceover then says, "Vote for President Johnson on November 3.

In captivity, these are not picky fish; They readily feed on different types of frozen, freeze-dried and live foods, such as tubifex worms, bean beetles (and larvae), bloodworms, brine shrimp, daphnia, flour beetles, krill, springtails, small or finely-chopped earthworms, black soldier fly larvae and cultured wingless fruit flies (Drosophila melanogaster). In particular, the tubifex worms and fruit flies are high in protein and nutrients, resulting in highly significant growth. A predominantly live food diet also provides nutrients for better reproductive performance. Ultimately, food variety is key, for health, but also for mimicking natural feeding habits. It was first described by Ferdinand Schultze in a catalog of specimens at the Zoological Museum of the Royal University of Berlin, published by Hinrich Lichtenstein in 1823. First import to Europe (Germany) by C.Ziggelkow, Hamburg in 1909 The genome of the angelfish was sequenced and assembled in 2022 by Indeever Madireddy, a high school student.

Alcohol or drug intoxication Cardiac arrhythmia Valvular heart disease Postprandial syndrome Hyperthyroidism Pheochromocytoma Post-gastric bypass hypoglycemia Generalized anxiety disorder Surreptitious insulin use Lab or blood draw error (lack of antiglycolytic agent in collection tube or during processing)

Sources: en.wikipedia.org

Background from the literature

== Expression == In insects, CSPs are found throughout the whole insect development process from eggs and larvae to nymphal and adult stages [4, 16-19]. In locusts, they are mainly expressed in the antennae, tarsi and legs, and found to be associated with phase change [3-4, 20-22]. CSPs are not the apanage of insects. They are also expressed in many various organisms such as crustacean, shrimp and many other arthropod species [23]. However, they are not specific to the arthropod kingdom. They are also expressed at the level of the bacterial superkingdom, demonstrating their existence not only in eukaryotes, but also in prokaryote organisms [23-24]. Prokaryote CSPs are twins or identical twins to insect CSPs [24]. They have been reported from bacterial species such as coccobacillus Acinetobacter baumannii, Macrococcus/Staphylococcus caseolyticus, the filamentous actinomycete Kitasatospora griseola, an Actinobacteria genus in the family Streptomycetaceae, and Escherichia coli (E. coli) which are known as common bacteria from the digestive tract, main prokaryotic secondary metabolites, opportunistic multi-drug resistant pathogens, high positive cytochrome c oxidase reactions, and symbionts of multiple insect species [24]. Their existence has been mentioned in plants, but this still needs to be demonstrated experimentally [25-26]. CSPs can be extracted from wasp venom [27]. In moths, nearly all CSPs are expressed in the female pheromone gland [9-14].

== Structure == The territorial matrix is composed of collagen fibrils and proteoglycans, forming a dense matrix around groups of chondrocytes, distinguishing itself from neighboring zones. It is located between the pericellular and interterritorial matrix. The territorial matrix is smaller in size (5-10 μm) than the interterritorial matrix, but larger than the pericellular matrix., The collagen that exists in this region is primarily type II collagen, with some types IX and XI. It is arranged in a finer, more interwoven network than in the interterritorial matrix. Proteoglycans like aggrecan and decorin provide resistance to compressive loads. Several glycoproteins are also present and play roles in the matrix assembly and stabilization. The close packing of the fibrils make the region denser, forming a mechanical barrier around chondrocytes.

The Regional Court of Hechingen and the Higher Regional Court of Stuttgart initially ruled in favor of the uncles in 1997, finding the equal-marriage clause contrary to public policy (sittenwidrig). After the Federal Court of Justice of Germany remanded the case, the lower courts reversed their position in favor of Georg Friedrich. His uncles then appealed to the Federal Constitutional Court of Germany, which ruled in 2004 that while historical house laws had lost all public-law status in 1919 and could not restrict testamentary freedom or mandate marriage requirements, family testators were still entitled to structure their wills privately under the civil code. On 19 October 2005, the Regional Court of Hechingen settled the estate dispute: Georg Friedrich was affirmed as the head of the house and principal heir under Louis Ferdinand's will, while the remaining children and heirs received their statutory compulsory shares (Pflichtteil) of the estate.

32S is produced by stellar nucleosynthesis inside massive stars, at a depth where the temperature exceeds 2.5×109 kelvins (4.50×109 °F), by the fusion of one nucleus of silicon plus one nucleus of helium. Because this nuclear reaction is part of the alpha process, which produces highly abundant elements, sulfur is the 10th most common element in the universe. Sulfur, usually in the sulfide oxidation state, is present in many types of meteorites. Ordinary chondrites contain on average 2.1% sulfur, and carbonaceous chondrites may contain as much as 6.6%. It is normally present as troilite (FeS), but there are exceptions, with carbonaceous chondrites containing free sulfur, sulfates and other sulfur compounds. The distinctive colors of Jupiter's volcanic moon Io are attributed to various forms of molten, solid, and gaseous sulfur. In July 2024, elemental sulfur was accidentally discovered to exist on Mars after the Curiosity rover drove over and crushed a rock, revealing sulfur crystals inside it. Sulfur is the fifth most common element by mass in the Earth. Elemental sulfur can be found near hot springs and volcanic regions in many parts of the world, especially along the Pacific Ring of Fire; such volcanic deposits are mined in Indonesia, Chile, and Japan. These deposits are polycrystalline, with the largest documented single crystal measuring 22 cm × 16 cm × 11 cm (8.7 in × 6.3 in × 4.3 in). Historically, Sicily was a major source of sulfur in the Industrial Revolution.

Sources: en.wikipedia.org

Reference notes

== Places == Mass City, Michigan, also known as Mass, an unincorporated community in the United States Maß (Lauer) (pronounced "mass"), a river of Bavaria, Germany, left tributary of the Lauer Massachusetts (abbreviated Mass or MA), a U.S. state in New England Massachusetts Bay (abbreviated Mass Bay), a bay off the U.S. state of the same name

=== Regulatory status === This medication first reached market in 1973. It is approved in 21 countries worldwide, which does not include its home country of Denmark. It was taken off the approved list in India in 2014, citing a lack of required information such as mandatory clinical trial results in its 1998 approval decision. It is approved in China.

==== Vitamin D2 ==== Plants Alfalfa (Medicago sativa subsp. sativa), shoot: 4.8 μg (192 IU) vitamin D2, 0.1 μg (4 IU) vitamin D3 Fungus, from USDA nutrient database, per 100 g: Mushrooms, portabella, exposed to ultraviolet light, raw: Vitamin D2: 11.2 μg (446 IU) Mushrooms, portabella, exposed to ultraviolet light, grilled: Vitamin D2: 13.1 μg (524 IU) Mushrooms, shiitake, dried: Vitamin D2: 3.9 μg (154 IU) Mushrooms, shiitake, raw: Vitamin D2: 0.4 μg (18 IU) Mushrooms, portabella, raw: Vitamin D2: 0.3 μg (10 IU) Mushroom powder, any species, illuminated with sunlight or artificial ultraviolet light sources Vitamin D2, or ergocalciferol is found in fungus (except alfalfa which is a plantae) and created from viosterol, which in turn is created when ultraviolet light activates ergosterol (which is found in fungi and named as a sterol from ergot). Any UV-irradiated fungus including yeast form vitamin D2. Human bioavailability of vitamin D2 from vitamin D2-enhanced button mushrooms via UV-B irradiation is effective in improving vitamin D status and not different from a vitamin D2 supplement according to study. For example, vitamin D2 from UV-irradiated yeast baked into bread is bioavailable. By visual assessment or using a chromometer, no significant discoloration of irradiated mushrooms, as measured by the degree of "whiteness", was observed making it hard to discover if they have been treated without labeling. Claims have been made that a normal serving (approx.

However, there are a few exceptions to this general rule, and enzymes such as aldose reductase, glucose-6-phosphate dehydrogenase, and methylenetetrahydrofolate reductase can use both coenzymes in some species.

Progesterone is metabolized into allopregnanolone and pregnanolone, which are neurosteroids and potent potentiators of the GABAA receptor. The conversion of progesterone into these metabolites is catalyzed by the enzymes 5α- and 5β-reductase and 3α-hydroxysteroid dehydrogenase, and occurs primarily in the liver, but also occurs in reproductive endocrine tissues, the skin, the brain, and other tissues. Due to extensive first-pass metabolism with oral progesterone, about 80 to 90% or more of progesterone is rapidly transformed into these metabolites, and massive quantities of these neurosteroids are consequently formed and circulate throughout the body and brain. It is for this reason that commonly reported side effects of oral progesterone include dizziness, drowsiness, sedation, somnolence, and fatigue. Both oral and sufficiently high doses of intramuscular progesterone can produce these sedative effects. However, compared to oral progesterone, the levels of these neurosteroids have been found to be very low with parenteral routes like vaginal and intramuscular progesterone. As with the bioavailability of oral progesterone, there is high interindividual variability in the formation and levels of allopregnanolone and pregnanolone with oral progesterone. As a result, some individuals may experience considerable central depressant effects with oral progesterone, whereas others may experience minimal such effects. With oral administration of progesterone, allopregnanolone and pregnanolone circulate at higher concentrations than progesterone.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Is AOD-9604 the same as growth hormone?

No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.

How is AOD-9604 regulated?

Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Network